Grades 3 to 4 toxic effects of thalidomide in patients with newly diagnosed MM
Regimen . | No. patients . | Thrombocytopenia, % . | Neutropenia, % . | Infection, % . | Peripheral neuropathy, % . | Reference . |
---|---|---|---|---|---|---|
Dexamethasone | ||||||
TD | 235 | 1 | 3 | ND | 2 | 52 *† |
TD | 103 | ND | ND | 7 | 7 | 31 * |
TD | 100 | ND | 0 | 4 | 4 | 32 |
TD | 50 | ND | ND | ND | 2 | 30 |
TD | 100 | ND | ND | ND | ND | 33 * |
Melphalan | ||||||
MPT | 129 | 3 | 16 | 10 | 8 | 37 * |
MPT | 125 | 14 | 48 | 13 | 6 | 38 * |
MPT | 113 | ND | 23‡ | ND | 20‡ | 39 * |
Doxorubicin | ||||||
ThaDD | 50 | 0 | 12 | 22 | 0 | 44 |
T-VAD doxil | 117 | 8‡ | 10‡ | 7 | 6‡ | 45 * |
T-VAD doxil | 39 | 15 | 15 | 21 | 5 | 40 |
Cyclophosphamide, CTD | 27 | ND | 4 | 7 | 4 | 47 |
Regimen . | No. patients . | Thrombocytopenia, % . | Neutropenia, % . | Infection, % . | Peripheral neuropathy, % . | Reference . |
---|---|---|---|---|---|---|
Dexamethasone | ||||||
TD | 235 | 1 | 3 | ND | 2 | 52 *† |
TD | 103 | ND | ND | 7 | 7 | 31 * |
TD | 100 | ND | 0 | 4 | 4 | 32 |
TD | 50 | ND | ND | ND | 2 | 30 |
TD | 100 | ND | ND | ND | ND | 33 * |
Melphalan | ||||||
MPT | 129 | 3 | 16 | 10 | 8 | 37 * |
MPT | 125 | 14 | 48 | 13 | 6 | 38 * |
MPT | 113 | ND | 23‡ | ND | 20‡ | 39 * |
Doxorubicin | ||||||
ThaDD | 50 | 0 | 12 | 22 | 0 | 44 |
T-VAD doxil | 117 | 8‡ | 10‡ | 7 | 6‡ | 45 * |
T-VAD doxil | 39 | 15 | 15 | 21 | 5 | 40 |
Cyclophosphamide, CTD | 27 | ND | 4 | 7 | 4 | 47 |